Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays | Zendy

Sven Pischke | Zendy; Carolynne SchwarzeZander | Zendy; Birgit Bremer | Zendy; Patrick Lehmann | Zendy; Steffen B. Wiegand | Zendy; A. Gisa | Zendy; Patrick Behrendt | Zendy; Christian P. Strassburg | Zendy; Michael P. Manns | Zendy; Heiner Wedemeyer | Zendy; Jürgen K. Rockstroh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays

Author(s) -

Sven Pischke,

Carolynne SchwarzeZander,

Birgit Bremer,

Patrick Lehmann,

Steffen B. Wiegand,

A. Gisa,

Patrick Behrendt,

Christian P. Strassburg,

Michael P. Manns,

Heiner Wedemeyer,

Jürgen K. Rockstroh

Publication year - 2015

Publication title -

intervirology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.641

H-Index - 61

eISSN - 1423-0100

pISSN - 0300-5526

DOI - 10.1159/000441472

Subject(s) - seroprevalence , hepatitis e virus , medicine , virology , antibody , cohort , hepatitis e , immunology , virus , serology , biology , genotype , biochemistry , gene

Cases of chronic hepatitis E virus (HEV) infection have been described in HIV-infected patients. There are several commercial anti-HEV assays, but anti-HEV seroprevalence rates differ largely depending on the assay used. The aim of this study was to (1) compare two commercial anti-HEV assays in a German cohort of HIV-positive individuals, and (2) determine whether HEV takes chronic courses in controlled HIV infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research